PE20160543A1 - Inhalador de polvo seco que contiene fluticasona y salmeterol - Google Patents
Inhalador de polvo seco que contiene fluticasona y salmeterolInfo
- Publication number
- PE20160543A1 PE20160543A1 PE2016000408A PE2016000408A PE20160543A1 PE 20160543 A1 PE20160543 A1 PE 20160543A1 PE 2016000408 A PE2016000408 A PE 2016000408A PE 2016000408 A PE2016000408 A PE 2016000408A PE 20160543 A1 PE20160543 A1 PE 20160543A1
- Authority
- PE
- Peru
- Prior art keywords
- dry powder
- salmeterol
- dose
- patient
- powder inhaler
- Prior art date
Links
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 5
- 229960004017 salmeterol Drugs 0.000 title abstract 3
- 229940112141 dry powder inhaler Drugs 0.000 title abstract 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 title 1
- 229960002714 fluticasone Drugs 0.000 title 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 229960000289 fluticasone propionate Drugs 0.000 abstract 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 239000000843 powder Substances 0.000 abstract 2
- 229960005018 salmeterol xinafoate Drugs 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/001—Particle size control
- A61M11/002—Particle size control by flow deviation causing inertial separation of transported particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
- A61M15/0076—Mechanical counters having a display or indicator on a drum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
- A61M15/0025—Mouthpieces therefor with caps
- A61M15/0026—Hinged caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
- A61M15/0078—Mechanical counters having a display or indicator on a strip
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta invencion proporciona un inhalador de polvo seco que comprende: un medicamento en polvo seco que comprende propionato de fluticasona, xinafoato de salmeterol y un vehiculo de lactosa; en donde, la dosis suministrada de salmeterol por accionamiento es menor a 50 microgramos; y en donde la dosis proporciona un FEV1 ajustado al valor inicial en un paciente de mas de 150 mL dentro de los 30 minutos de haber recibido la dosis. Un metodo de tratamiento de un paciente incluye la administracion a un paciente de un medicamento en polvo seco que tiene propionato de fluticasona, xinafoato de salmeterol y un vehiculo de lactosa; en donde, la dosis suministrada de salmeterol por accionamiento es menor a 50 microgramo; y en donde la dosis proporciona un FEV1 ajustado al valor inicial en un paciente de mas de 150 mL dentro de los 30 minutos de haber recibido la dosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887589P | 2013-10-07 | 2013-10-07 | |
| US201361888301P | 2013-10-08 | 2013-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160543A1 true PE20160543A1 (es) | 2016-06-05 |
Family
ID=51743574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000408A PE20160543A1 (es) | 2013-10-07 | 2014-10-06 | Inhalador de polvo seco que contiene fluticasona y salmeterol |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20160243320A1 (es) |
| EP (1) | EP3054920B1 (es) |
| JP (1) | JP6543620B2 (es) |
| KR (1) | KR102364945B1 (es) |
| CN (1) | CN105636630B (es) |
| AU (1) | AU2014332191B2 (es) |
| BR (1) | BR112016007771B1 (es) |
| CA (1) | CA2926432A1 (es) |
| CL (1) | CL2016000735A1 (es) |
| DK (1) | DK3054920T3 (es) |
| EA (1) | EA035329B1 (es) |
| ES (1) | ES2863198T3 (es) |
| HK (1) | HK1222127A1 (es) |
| HU (1) | HUE055042T2 (es) |
| IL (1) | IL244959B (es) |
| MX (1) | MX374870B (es) |
| PE (1) | PE20160543A1 (es) |
| PH (1) | PH12016500619A1 (es) |
| PL (1) | PL3054920T3 (es) |
| PT (1) | PT3054920T (es) |
| TW (1) | TWI673070B (es) |
| WO (1) | WO2015054124A2 (es) |
| ZA (1) | ZA201601960B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013036881A2 (en) | 2011-09-07 | 2013-03-14 | Syphase, Llc | Dry powder inhalation device |
| US20160243320A1 (en) * | 2013-10-07 | 2016-08-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Dry powder inhaler |
| AU356105S (en) * | 2013-11-29 | 2014-06-24 | Norton Waterford Ltd | Respiratory apparatus |
| AU356104S (en) * | 2013-11-29 | 2014-06-24 | Norton Waterford Ltd | Respiratory apparatus |
| USD752204S1 (en) * | 2014-03-10 | 2016-03-22 | Civitas Therapeutics, Inc. | Indicator for an inhaler |
| USD752734S1 (en) | 2014-03-10 | 2016-03-29 | Civitas Therapeutics, Inc. | Inhaler grip |
| USD755367S1 (en) * | 2014-03-10 | 2016-05-03 | Civitas Therapeutics, Inc. | Indicator for an inhaler |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| CN107095875B (zh) * | 2016-02-23 | 2022-03-18 | 天津金耀集团有限公司 | 一种昔奈酸沙美特罗丙酸氟替卡松复方粉吸入剂组合物 |
| ES3034249T3 (en) * | 2016-04-12 | 2025-08-14 | Biocorp Production S A S | Metered dose inhaler observance system |
| CN106267484A (zh) * | 2016-08-08 | 2017-01-04 | 中山市美捷时包装制品有限公司 | 一种干粉吸入装置的定量供料机构 |
| USD832998S1 (en) * | 2016-10-21 | 2018-11-06 | Norton (Waterford) Limited | Inhaler |
| USD852947S1 (en) * | 2016-10-21 | 2019-07-02 | Norton (Waterford) Limited | Inhaler |
| USD832997S1 (en) * | 2016-10-21 | 2018-11-06 | Norton (Waterford) Limited | Inhaler |
| ES2884802T3 (es) * | 2016-11-18 | 2021-12-13 | Norton Waterford Ltd | Dispositivo de administración de fármacos con componentes electrónicos |
| USD853555S1 (en) * | 2017-01-03 | 2019-07-09 | Norton (Waterford) Limited | Inhaler |
| GB201700727D0 (en) * | 2017-01-16 | 2017-03-01 | Teva Pharma | Inhalers and airflow adaptors therefor |
| CA3057683A1 (en) | 2017-03-28 | 2018-10-04 | Concentrx Pharmaceuticals, Inc. | Devices and methods for delivering dry powder medicaments |
| CN107715264B (zh) * | 2017-10-12 | 2021-01-29 | 上海新黄河制药有限公司 | 一种粉雾剂装置制剂粉末团聚物的分散/解聚装置 |
| CN107737393B (zh) * | 2017-10-12 | 2020-08-28 | 上海新黄河制药有限公司 | 一种用于粉雾剂吸入装置的制剂雾化流道 |
| US11951247B2 (en) | 2017-12-13 | 2024-04-09 | Emphasys Lmportadora Exportadora E Distribuidora Ltda. | Dry powder inhaler |
| USD948704S1 (en) * | 2019-07-26 | 2022-04-12 | Lupin Ltd. | Inhaler |
| USD948703S1 (en) * | 2019-07-26 | 2022-04-12 | Lupin Ltd. | Inhaler |
| USD949323S1 (en) * | 2019-07-26 | 2022-04-19 | Lupin Ltd. | Inhaler |
| USD949324S1 (en) * | 2019-07-26 | 2022-04-19 | Lupin Ltd. | Inhaler |
| USD1006213S1 (en) * | 2020-02-14 | 2023-11-28 | Aptar France Sas | Inhaler |
| USD1006214S1 (en) * | 2020-02-14 | 2023-11-28 | Aptar France Sas | Inhaler |
| EP4142528A1 (en) * | 2020-04-27 | 2023-03-08 | JT International SA | Aerosol generation device |
| GB202012742D0 (en) * | 2020-08-14 | 2020-09-30 | Norton Waterford Ltd | An inhalable medicament |
| IL300652A (en) * | 2020-08-14 | 2023-04-01 | Norton Waterford Ltd | Inhalable formulation of fluticasone propionate and albuterol sulfate |
| KR102782140B1 (ko) | 2022-08-25 | 2025-03-18 | 주식회사 케이티앤지 | 흡입기 |
| KR102783650B1 (ko) | 2022-09-14 | 2025-03-19 | 주식회사 케이티앤지 | 흡입기 |
| KR102864455B1 (ko) | 2022-09-14 | 2025-09-26 | 주식회사 케이티앤지 | 흡입기 |
| KR102885446B1 (ko) | 2022-09-19 | 2025-11-14 | 주식회사 케이티앤지 | 흡입기 |
| KR20240107439A (ko) | 2022-12-30 | 2024-07-09 | 주식회사 케이티앤지 | 흡입기 |
| EP4487837A1 (en) | 2023-07-07 | 2025-01-08 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate for the treatment of asthma |
| WO2025012114A1 (en) | 2023-07-07 | 2025-01-16 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate for the treatment of asthma |
| WO2025012115A1 (en) | 2023-07-07 | 2025-01-16 | Norton (Waterford) Limited | An inhalable formulation of fluticasone propionate and albuterol sulfate for the treatment of asthma |
| WO2025199032A1 (en) * | 2024-03-18 | 2025-09-25 | Transpire Bio Inc. | Trigger mechanism and powder inhalation device |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| TWI224514B (en) * | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Dose metering system for medicament inhaler |
| AR028747A1 (es) * | 2000-06-23 | 2003-05-21 | Norton Health Care Ltd | Desaglomerador para inhalador de polvo seco accionado por la respiracion, un inhalador de polvo seco y un metodo de desaglomeracion de polvo seco. |
| GB0124523D0 (en) * | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| DE60239639D1 (de) * | 2002-07-31 | 2011-05-12 | Chiesi Farma Spa | Pulverinhalator |
| CN1694689A (zh) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| WO2009008001A2 (en) * | 2007-04-30 | 2009-01-15 | Sun Pharma Advanced Research Company Limited | Inhalation device |
| JP2008301847A (ja) * | 2007-06-05 | 2008-12-18 | Canon Inc | 吸入装置及びその駆動方法 |
| EP2197444A1 (en) * | 2007-09-12 | 2010-06-23 | Glaxo Group Limited | Novel combination of therapeutic agents |
| TWI792140B (zh) * | 2009-05-29 | 2023-02-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道遞送二或更多種活性藥劑的組成物、方法與系統 |
| GB0919465D0 (en) * | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
| WO2011145109A1 (en) * | 2010-05-20 | 2011-11-24 | Sun Pharma Advanced Research Company Ltd., | Dry powder inhalation composition |
| US20160243320A1 (en) * | 2013-10-07 | 2016-08-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Dry powder inhaler |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
-
2014
- 2014-10-06 US US15/027,660 patent/US20160243320A1/en not_active Abandoned
- 2014-10-06 CA CA2926432A patent/CA2926432A1/en not_active Withdrawn
- 2014-10-06 ES ES14786419T patent/ES2863198T3/es active Active
- 2014-10-06 EP EP14786419.3A patent/EP3054920B1/en active Active
- 2014-10-06 CN CN201480055333.2A patent/CN105636630B/zh active Active
- 2014-10-06 US US14/507,210 patent/US9066957B2/en active Active
- 2014-10-06 MX MX2016004316A patent/MX374870B/es active IP Right Grant
- 2014-10-06 PT PT147864193T patent/PT3054920T/pt unknown
- 2014-10-06 KR KR1020167011976A patent/KR102364945B1/ko active Active
- 2014-10-06 JP JP2016520581A patent/JP6543620B2/ja not_active Expired - Fee Related
- 2014-10-06 AU AU2014332191A patent/AU2014332191B2/en active Active
- 2014-10-06 EA EA201690738A patent/EA035329B1/ru not_active IP Right Cessation
- 2014-10-06 BR BR112016007771-7A patent/BR112016007771B1/pt active IP Right Grant
- 2014-10-06 HU HUE14786419A patent/HUE055042T2/hu unknown
- 2014-10-06 PE PE2016000408A patent/PE20160543A1/es unknown
- 2014-10-06 PL PL14786419T patent/PL3054920T3/pl unknown
- 2014-10-06 HK HK16110356.9A patent/HK1222127A1/zh unknown
- 2014-10-06 WO PCT/US2014/059285 patent/WO2015054124A2/en not_active Ceased
- 2014-10-06 DK DK14786419.3T patent/DK3054920T3/da active
- 2014-10-07 TW TW103134890A patent/TWI673070B/zh not_active IP Right Cessation
-
2016
- 2016-03-22 ZA ZA2016/01960A patent/ZA201601960B/en unknown
- 2016-03-30 CL CL2016000735A patent/CL2016000735A1/es unknown
- 2016-04-05 PH PH12016500619A patent/PH12016500619A1/en unknown
- 2016-04-06 IL IL244959A patent/IL244959B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20160543A1 (es) | Inhalador de polvo seco que contiene fluticasona y salmeterol | |
| PE20171258A1 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafoato de salmeterol | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
| BR112012023407A2 (pt) | composição em pó farmacêutica para instalação, e, processo para a preparação da mesma. | |
| MX2020003436A (es) | Inhalador de polvo seco y metodo de uso. | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| BR112015022650A2 (pt) | inibidores de cinase induzível por sal macrocíclico | |
| AR100368A1 (es) | Tratamiento de trastornos respiratorios | |
| DOP2014000269A (es) | Nueva dosificación y formulación | |
| BR112015023917A2 (pt) | método para determinar a atividade de forma potenciada ativada de substância | |
| CY1117596T1 (el) | Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης | |
| MX2015016418A (es) | Dihidroetorfina para proporcionar el alivio del dolor y la anestesia. | |
| BR102012028120B8 (pt) | Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento | |
| BR112014030288A8 (pt) | composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila | |
| AR102903A1 (es) | Inhalador de polvo seco | |
| AR094287A1 (es) | Metodos y composiciones para administracion de oxibutinina | |
| BR112018072183A2 (pt) | composição farmacêutica, e, método para prevenir uma doença de pele | |
| BR112014003907A2 (pt) | método para preparar inalador pulverizado de dose medida para tratar doença respiratória | |
| UY35900A (es) | Nueva dosificación y formulación | |
| TH173838A (th) | เครื่องพ่นละอองยาผงแห้ง | |
| BR112019005133A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente sofrendo ou susceptível de sofrer de um distúrbio respiratório, para melhorar a estabilidade de uma composição farmacêutica, para melhoria do desempenho de dispersão em aerossol de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica. |